The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness
Daniel Hormaechea‐Agulla(Baylor College of Medicine), Raúl M. Luque(Instituto de Salud Carlos III), Enrique Gómez‐Gómez(Instituto Maimónides de Investigación Biomédica de Córdoba), Rosa Ortega‐Salas(Instituto Maimónides de Investigación Biomédica de Córdoba), Rafael Sánchez‐Sánchez(Instituto Maimónides de Investigación Biomédica de Córdoba), Manuel D. Gahete(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), María M. Moreno(Instituto Maimónides de Investigación Biomédica de Córdoba), Fernando L‐López(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Juan M. Jiménez‐Vacas(Instituto de Salud Carlos III), Michael D. Culler(Ipsen (United States)), Julia Carrasco‐Valiente(Instituto Maimónides de Investigación Biomédica de Córdoba), Esther Rivero‐Cortés(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Alejandro Ibáñez‐Costa(Instituto de Salud Carlos III), André Sarmento‐Cabral(University of Illinois Chicago), Justo P. Castaño(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Natia Tsomaia(Ipsen (France)), M.J. Requena(Instituto Maimónides de Investigación Biomédica de Córdoba), Steve M. Swanson(University of Wisconsin–Madison), J. Valero-Rosa(Instituto Maimónides de Investigación Biomédica de Córdoba)
Cited by 51
Related Papers
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
Does gut hormone PYY3–36 decrease food intake in rodents?
|Nature|2004|295
International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
|Pharmacological Reviews|2018|251
PYY3‐36 as an anti‐obesity drug target
|Obesity Reviews|2005|121